Global leading supplier of Clindamycin and other API, 90% for export, 50% market shares in the world. Fosun Chemical Investment: 2003. IPO on December 26, 2006 on the ShenZhen Stock Exchange, trade code: 002099. 

Website: http://www.hisoar.com

A leading supplier of pharmaceutical raw materials and special resins for ion exchange, absorbents and special applications for worldwide markets. Amicogen develops and manufactures API, intermediate and fine chemicals in accordance with related GMP.Principle Fund III Investment: 2016.

Website: http://www.lksz.cn

Genechem is one of the leading disease key gene diagnosis and treatment providers, and the largest RNA interference and lentivirus research service provider in China. Principle Fund III Investment: 2014.

Website: http://www.genechem.com.cn

Bioregen is an innovative biomaterial firm with unique sodium hyaluronate technology platform, providing international-leading solutions for postoperative adhesions, especially for gynecologic surgeries. Three anti-adhesion products have been launched and are highly recognized by globally top clinical experts. Principle Fund III Investment: 2016.

Website: http://www.bioregenmed.com

Genesky is a fast-growing biotech firm with innovative gene detecting technology. It provides efficient, low-cost gene detecting products to pregnant couples and newborn babies. Principle Fund III Investment: 2015.

Website: http://www.geneskies.com

Accela is a leading supplier in the field of catalog building blocks and CDMO services for innovative drugs. Accela provides chemical reagents, catalog building blocks, customized synthesis and CDMO of drug molecule intermediates. Building on the outstanding organic synthesis expertise and manufacturing techniques, Accela has been serving blue-chip customers and enjoys good brand reputation in the industry. The R&D team has over 15 years’ successful track record, and strives to serve the drug development supply chain both in China and across the globe.  

Website：http://www.shao-yuan.com